A Rare and Deadly Cancer May Have an Unexpected New Vulnerability
Reported byUniversity of Vermont ↗·Sourced by Goodlede
A University of Vermont research team achieved disease control in 67% of mesothelioma patients in a phase one clinical trial by using an experimental drug (thiostrepton-derived) that blocks the PRX3 antioxidant enzyme, allowing reactive oxygen species to accumulate and kill tumor cells—a reversal of decades of failed antioxidant approaches.
Phase one trial results; stage two results expected later in 2026.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at University of Vermont
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede